Pulmonary hypertension in chronic heart failure

International Journal of Clinical Practice

Volumn 63, Issue SUPPL. 161, 2009, Pages 4-10

  Bonderman, D ^a   Martischnig, A M ^a   Moertl, D ^a   Lang, I M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; DARUSENTAN; DOBUTAMINE; ENDOTHELIN 1; ENOXIMONE; GLYCERYL TRINITRATE; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTAGLANDIN E1; SILDENAFIL; SITAXSENTAN; SORAFENIB; TEZOSENTAN; VASCULOTROPIN; VASOACTIVE AGENT; VASODILATOR AGENT;

CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG MECHANISM; EXERCISE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LUNG EDEMA; LUNG PRESSURE; MORBIDITY; MORTALITY; NONHUMAN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; VASOCONSTRICTION;

EID: 58849120920     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01950.x     Document Type: Review

References (60)

1. Ghio S, Gavazzi A, Campana C et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001 37 : 183 8.
2. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 26 : 1115 40.
3. Galie N, Torbicki A, Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004 25 : 2243 78.
4. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007 93 : 1137 46.
5. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999 34 : 1802 6.
6. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992 19 : 48 54.
7. Harris P, Heath D. The Human Pulmonary Circulation, 3rd edn. New York : Churchill Livingston, 1986.
8. Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999 18 : 1126 32.
9. Capomolla S, Febo O, Guazzotti G et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 2000 19 : 426 38.
10. Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997 29 : 153 9.
11. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000 102 : 1718 23.
12. Huang W, Kingsbury MP, Turner MA, Donnelly JL, Flores NA, Sheridan DJ. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 2001 49 : 207 17.
13. Fowler NO Jr., Westcott RN, Scott RC. Pulmonary artery diastolic pressure: its relationship to pulmonary arteriolar resistance and pulmonary 'capillary' pressure. J Clin Invest 1952 31 : 72 9.
14. Buchbinder N, Ganz W. Hemodynamic monitoring: invasive techniques. Anesthesiology 1976 45 : 146 55.
15. Cooper CJ, Landzberg MJ, Anderson TJ et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996 93 : 266 71.
16. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988 37 : 2495 501.
17. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991 69 : 1088 96.
18. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 332 : 411 5.
19. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989 86 : 2863 7.
20. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol 1999 126 : 391 8.
21. Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996 72 : 109 48.
22. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008 153 : 1105 19.
23. Molenaar P, O'Reilly G, Sharkey A et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 1993 72 : 526 38.
24. Zellers TM, McCormick J, Wu Y. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am J Physiol 1994 267 : H139 47.
25. Lippton HL, Hauth TA, Summer WR, Hyman AL. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol 1989 66 : 1008 12.
26. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992 85 : 504 9.
27. Sakai S, Miyauchi T, Sakurai T et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 1996 28 : 1580 8.
28. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005 115 : 2811 21.
29. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008 33 : 278 91.
30. Ray L, Mathieu M, Jespers P et al. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol 2008 93 : 434 42.
31. Hoeper MM, Lee SH, Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006 48 : 2546 52.
32. Baim D. Cardiac Catheterization, Angiography, and Intervention. Baltimore, MD : Lippincott Williams & Wilkins, 1996.
33. Franciosa JA, Baker BJ, Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 1985 110 : 807 13.
34. Tumminello G, Lancellotti P, Lempereur M, D'Orio V, Pierard LA. Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J 2007 28 : 569 74.
35. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995 75 : 1282 3.
36. Koelling TM, Kirmse M, Di Salvo TG, Dec GW, Zapol WM, Semigran MJ. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998 81 : 1494 7.
37. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002 105 : 1663 8.
38. Kjaergaard J, Akkan D, Iversen KK et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007 99 : 1146 50.
39. Hulsmann M, Stanek B, Frey B et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998 32 : 1695 700.
40. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report. J Heart Lung Transplant 2001 20 : 805 15.
41. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988 7 : 331 6.
42. Costanzo MR, Augustine S, Bourge R et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995 92 : 3593 612.
43. Tenderich G, Koerner MM, Stuettgen B et al. Does preexisting elevated pulmonary vascular resistance (transpulmonary gradient > 15 mmHg or > 5 Wood) predict early and long-term results after orthotopic heart transplantation? Transplant Proc 1998 30 : 1130 1.
44. Butler J, Stankewicz MA, Wu J et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant 2005 24 : 170 7.
45. von Scheidt W, Costard-Jaeckle A, Stempfle HU et al. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant 2006 25 : 1070 6.
46. Mehra MR, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates. J Heart Lung Transplant 2006 25 : 1024 42.
47. Virgolini I, Auinger C, Weissel M et al. Increase in left ventricular ejection fraction (LVEF) induced by PGE1 and PGI2 Beneficial effect of long-term PGE1-treatment in left ventricular heart failure. Prog Clin Biol Res 1989 301 : 463 7.
48. Auinger C, Virgolini I, Weissel M, Bergmann H, Sinzinger H. Prostacyclin I2 (PGI2) increases left ventricular ejection fraction (LVEF). Prostaglandins Leukot Essent Fatty Acids 1989 36 : 149 54.
49. Virgolini I, Kaliman J, Fitscha P, O'Grady J, Rogatti W, Sinzinger H. Beneficial effect of long-term PGE1-treatment in left ventricular heart failure. Prostaglandins Leukot Essent Fatty Acids 1989 38 : 177 80.
50. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 1982 50 : 320 4.
51. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003 108 : 2184 90.
52. Luscher TF, Enseleit F, Pacher R et al. Hemodynamic and neurohumoral effects of selective endothelin A [ET(A)] receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002 106 : 2666 72.
53. Califf RM, Adams KF, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997 134 : 44 54.
54. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002 85 : 195 7.
55. Anand I, McMurray J, Cohn JN et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004 364 : 347 54.
56. Lewis GD, Shah R, Shahzad K et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007 116 : 1555 62.
57. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007 50 : 2136 44.
58. Stanek B, Sturm B, Frey B et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 1999 18 : 358 66.
59. Krell MJ, Kline EM, Bates ER et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986 112 : 787 91.
60. Martin J, Siegenthaler MP, Friesewinkel O et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 2004 25 : 971 7.